{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=13",
    "query": {
      "intervention": "IVIG",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 291,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T01:03:14.351Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02697292",
      "title": "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autoimmune Epilepsy"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-02",
      "completion_date": "2018-12-03",
      "has_results": true,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697292"
    },
    {
      "nct_id": "NCT01736579",
      "title": "Long-Term Study of IGIV, 10% in Alzheimer´s Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer´s Disease"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "51 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2012-11-29",
      "completion_date": "2013-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736579"
    },
    {
      "nct_id": "NCT00634569",
      "title": "Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immune Deficiency Disease"
      ],
      "interventions": [
        {
          "name": "Flebogamma 5% DIF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-05",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 7,
      "location_summary": "St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634569"
    },
    {
      "nct_id": "NCT05350774",
      "title": "Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Inflammation",
        "Neuroinflammation",
        "Microvascular Thrombosis"
      ],
      "interventions": [
        {
          "name": "IV normal saline",
          "type": "DRUG"
        },
        {
          "name": "IV immunoglobulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 45,
      "start_date": "2023-07-10",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05350774"
    },
    {
      "nct_id": "NCT06305780",
      "title": "RECOVER-AUTONOMIC Platform Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long Covid19",
        "Long Covid-19"
      ],
      "interventions": [
        {
          "name": "IVIG + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine Placebo + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine Placebo + Usual Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kanecia Obie Zimmerman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 381,
      "start_date": "2024-03-11",
      "completion_date": "2025-07-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 50,
      "location_summary": "Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more",
      "locations": [
        {
          "city": "Opelika",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305780"
    },
    {
      "nct_id": "NCT01158157",
      "title": "VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox Vaccine Adverse Reaction"
      ],
      "interventions": [
        {
          "name": "ACAM2000",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-09-13",
      "completion_date": "2012-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 1,
      "location_summary": "Altamonte Springs, Florida",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158157"
    },
    {
      "nct_id": "NCT02549170",
      "title": "A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.25% albumin placebo solution with rHuPH20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMMAGARD LIQUID/KIOVIG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMUNEX®-C",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2015-12-15",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549170"
    },
    {
      "nct_id": "NCT04530487",
      "title": "Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Desmoplastic Small Round Cell Tumor",
        "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Desmoplastic Small Round Cell Tumor",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Desmoplastic Small Round Cell Tumor",
        "Refractory Malignant Peripheral Nerve Sheath Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Lapine T-Lymphocyte Immune Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-08-19",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530487"
    },
    {
      "nct_id": "NCT06920004",
      "title": "A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "CIDP",
        "CIDP - Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "empasiprubart",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IVIg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "empasiprubart-placebo",
          "type": "OTHER"
        },
        {
          "name": "IVIg-placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2025-08-22",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06920004"
    },
    {
      "nct_id": "NCT01406470",
      "title": "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Green Cross Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-09",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-20T01:03:14.351Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01406470"
    }
  ]
}